Cells were grown in medium containing drugs and cell viability was determined by MTT assay. A series of verapamil concentration (0-10 M) were added to medium for 1 h before addition of daunorubicin. Relative daunorubicin resistance: IC 50 of cells relative to sensitive K562 cells (the value was set arbitrarily at 1). Value are expressed as the means ± s.d. of three independent experiments. The numbers in parentheses are absolute values of IC 50 (nM).
produced an apparently dose-dependent increase in sensitivity of K562R to DNR, the maximal reversal (verapamil 10 M) was 20-fold. In contrast, the sensitivity of K562R with anti-mdr ribozyme cells was able to be restored completely by combining verapamil even if verapamil was at a lower concentration (1 M). Transfecting with empty vector has no effect on the sensitivity to an anticancer drug. These results suggested that the combination of anti-mdr1 ribozyme and verapamil have synergistic effects on reversing multidrug resistance. This indicates that in combination with ribozyme, an efficient dose of verapamil to reverse MDR can be reduced to the degree that serious toxicity limiting its clinical application will not appear in clinical MDR reversal. This will be one possible strategy to reverse MDR and may be used as a new therapy in the treatment of patients with anticancerresistant leukemia and other cancers. However, we report a patient with cytarabine-induced aseptic meningitis. To our knowledge, only three such cases have been reported. [2] [3] [4] This is the first case to show that any route of administration can induce DIAM and recurrence can be prevented by corticosteroids and H1-receptor-blocking agents.
University of Medical
In a 15-year-old previously healthy girl with a 3-week history of progressive fatigue, headache and muscle pains, bone marrow examination showed lymphoblasts with FAB-L3 morphology and expression of kappa-chains on the cells surface, confirming B cell leukaemia. Further evaluation showed no extramedullar involvement. CSF was initially unremarkable, ie 1/mm 3 cells, protein 0.26 g/l, glucose 3.5 mmol/l and on cytospin slides no lymphoblasts. The patient was treated according to the LMB 86 protocol. 5 After the first course (COP, with cytarabine intrathecally only), CSF protein had risen to 0.81 g/l (Figure 1) . The final day of the second course (COPADM, with
Figure 1
COP: prednisolone, vincristine, cyclophophamide, 3× TIT (= triple intrathecal therapy, ie methotrexate, 40 mg cytarabine, prednisolone); COPADM: prednisolone, vincristine, cyclophosphamide, adriamycin, high-dose methotrexate, 3× TIT; CYVE: etoposide, 5× 3000 mg/m 2 cytarabin intravenously; maintenance 1: high-dose methotrexate, cyclophosphamide, adriamycin, vincristin, intrathecal with methotrexate and prednisolone; maintenance 2: 5× 200 mg/m 2 cytarabine subcutaneously, etoposide, 2× TIT (note: intrathecal therapy was not given during the second maintenance 2 course). cytarabine i.t. only), the girl had fever (38°C), headache and nausea. Examination revealed mild nuchal rigidity. She was in aplasia (WBC 0.12 × 10 9 /l), CSF showed 2/mm 3 cells, protein 0.77 g/l. Since bacterial meningitis was suspected, antibiotic treatment was started. Although from the blood S. mitis was cultured, the CSF culture remained negative. At the time that aplasia had resolved (12 days later) CSF was as follows: polynuclear cells 1200/mm 3 , protein 2.0 g/l , glucose 1.1 mmol/l. Despite effective antibiotic therapy symptoms persisted and aseptic meningitis was considered. Two weeks after the start of the first COPADM course, rigidity and headaches had resolved and the second COPADM course was given. The CSF still showed an increased protein 1.5 g/l, but cell count was nearly normal (7 cell/mm 3 ). Immediately after this course the girl complained of pain in her legs and became confused. Haloperidol had to be given for 1 week. The 3rd day of the next course (CYVE, high-dose cytarabine) the patient suffered again from severe headache. On physical examination nuchal rigidity was found. In the following days hyperaesthesia was noted in both legs; areflexia and loss of sensation and muscle weakness below L1 was seen; incontinence occurred. Signs were compatible with transverse myelitis below L1. CSF showed 1400/mm 3 polymorphonuclear cells and 1.35 g/l protein. During the following course (maintenance 1, no cytarabine) symptoms partially resolved. However, following the next course (maintenance 2, containing subcutaneous cytarabine) symptoms aggravated. During the following course (maintenance 1), recovery was noted. During the final course, containing similar amounts of cytarabine (the second maintenance 2 course), corticosteroids and clemastin (H1-receptor antagonist) were added in an attempt to prevent DIAM; the intrathecal cytarabine was omitted. The neurological symptoms did not recur. CSF stayed unremarkable. Throughout the whole period, CSF bacterial and viral examinations were done repeatedly and were negative. Also, CT and MRI examinations were normal. Unfortunately a leukaemia relapse was detected 10 months after initial diagnosis from which the patient died soon afterwards.
Neurotoxicity of high-dose cytarabine is well recognised. Most common are cerebellar syndrome, seizures, leukencephalopathy and peripheral neuropathy. In a few cases transverse myelitis has been described. 6 Our case illustrates that cytarabine can cause aseptic meningitis and even low-dose cytarabine, given intrathecally, can induce DIAM. Considering our patient it can be debated whether transverse myelitis after cytarabine treatment, as reported in a few cases, is an extreme expression of DIAM. To our knowledge only three cases of cytarabine-induced DIAM have been reported previously. Doses varied from 500 mg/m 2 to 24 g in total. Aseptic meningitis from cytarabine can last up to 8 weeks and was in one case complicated by cerebellar dysfunction. In all cases complete recovery was seen.
2-4
DIAM has a high recurrence rate; 29 out of the 176 cases reviewed by Moris et al. 1 In the report of Flasshove DIAM recurrence was noted at rechallenge.
2 This was also seen in our patient. The pathogenesis may vary for different classes of drugs. Since DIAM is often noted in conjunction with facial edema, skin rash and eosinophilia, the first hypothesis assumes that drug hypersensitivity is causative. However, it remains unexplained what confines the reaction largely to the CSF compartment. Our patient did not have signs of facial edema or skin rash, but we noted relative eosinophilia after both maintenance 2 courses (both times up to 8% while she was still granulocytopenic). Since corticosteroids and a H1-receptor blocking agent were able to prevent a new course of DIAM in our patient, hypersensitivity might indeed be the pathogenic mechanism. Although during the second maintenance 2 course the intrathecal cytarabine was omitted, the high number of mononuclear cells and the severity of symptoms, as compared to the courses in which cytarabine was given only intrathecally, makes an assumption that subcutaneous cytarabine does not induce DIAM rather unlikely. Since DIAM is often mentioned in SLE and after OKT3 treatment, the second hypothesis is immunologic dysregulation. Thirdly, in patients treated with intravenous immunoglobulins, vasculitis, due to increased viscosity of the blood, has been suggested. Finally, some have proposed that DIAM is caused by immune complexes.
1
Since no clinical symptoms or laboratory characteristics distinguish DIAM from other causes of meningitis, it is important to consider its possibility in all patients with aseptic meningitis. Signs of asymptomatic aseptic meningitis can be seen in the CSF after a very limited number of intrathecal cytarabine injections. Severe symptoms may occur after subcutaneous and intravenous treatment. Although in most cases of DIAM the offensive drug is withdrawn, our observation suggests that recurrence of cytarabine-related DIAM might be prevented by prednisone and H1-receptor antagonists.
